{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T22:33:24Z","timestamp":1792103604585,"version":"4.4.0"},"reference-count":36,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2023,4,21]],"date-time":"2023-04-21T00:00:00Z","timestamp":1682035200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Physiol."],"abstract":"<jats:p><jats:bold>Background:<\/jats:bold> The Japanese drug use system allowed the once-daily use of inhaled corticosteroid fluticasone furoate (FF) combined with a long-acting beta-2 agonist vilanterol (VI) and a long-acting muscarinic antagonist umeclidinium (UMEC) against asthma on 18 February 2021. We investigated the real-world effects of these drugs (FF\/UMEC\/VI) mainly on lung function tests.<\/jats:p><jats:p><jats:bold>Methods:<\/jats:bold> This was an open-label, uncontrolled, within-group time-series (before-after) study. Prior asthma treatment (inhaled corticosteroid with\/without a long-acting beta-2 agonist with\/without a long-acting muscarinic antagonist) was switched to FF\/UMEC\/VI 200\/62.5\/25\u00a0\u03bcg. Subjects were evaluated by lung function tests prior to, and 1\u20132\u00a0months after, initiation of FF\/UMEC\/VI 200\/62.5\/25\u00a0\u03bcg. Patients were asked questions regarding the asthma control test and preference for drugs.<\/jats:p><jats:p><jats:bold>Results:<\/jats:bold> Overall, 114 asthma outpatients (97% Japanese) were enrolled from February 2021 to April 2022: 104 subjects completed the study. Forced expiratory volume in 1\u00a0s, peak flow, and asthma control test score of FF\/UMEC\/VI 200\/62.5\/25\u00a0\u03bcg-treated subjects were significantly increased (<jats:italic>p<\/jats:italic> &amp;lt; 0.001, <jats:italic>p<\/jats:italic> &amp;lt; 0.001, and <jats:italic>p<\/jats:italic> &amp;lt; 0.01, respectively). In contrast with FF\/VI 200\/25\u00a0\u03bcg, instantaneous flow at 25% of the forced vital capacity and expiratory reserve volume were significantly increased by FF\/UMEC\/VI 200\/62.5\/25\u00a0\u03bcg (<jats:italic>p<\/jats:italic> &amp;lt; 0.01, <jats:italic>p<\/jats:italic> &amp;lt; 0.05, respectively). Sixty-six percent of subjects declared they wanted to continue FF\/UMEC\/VI 200\/62.5\/25\u00a0\u03bcg in the future. Adverse effects, mainly local, were seen in 30% of patients, but no serious adverse effects were seen.<\/jats:p><jats:p><jats:bold>Conclusion:<\/jats:bold> Once-daily FF\/UMEC\/VI 200\/62.5\/25\u00a0\u03bcg was effective against asthma without serious adverse events. This is the first report that demonstrated FF\/UMEC\/VI dilated peripheral airways using lung function tests. This evidence on drug effects may improve our understanding of pulmonary physiology and the pathophysiology of asthma.<\/jats:p>","DOI":"10.3389\/fphys.2023.1131949","type":"journal-article","created":{"date-parts":[[2023,4,21]],"date-time":"2023-04-21T04:24:15Z","timestamp":1682051055000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":5,"title":["Real-world effects of once-daily inhaled steroid (fluticasone furoate) combined with long-acting beta-2 agonist (vilanterol) and long-acting muscarinic antagonist (umeclidinium) on lung function tests of asthma patients in Japan"],"prefix":"10.3389","volume":"14","author":[{"given":"Akira","family":"Umeda","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hisato","family":"Shimada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tateki","family":"Yamane","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Taichi","family":"Mochizuki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasushi","family":"Inoue","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenji","family":"Tsushima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuya","family":"Miyagawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Atsumi","family":"Mochida","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroshi","family":"Takeda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasumasa","family":"Okada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katsunori","family":"Masaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masako","family":"Matsusaka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koichi","family":"Fukunaga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2023,4,21]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1007\/s40262-012-0021-x","article-title":"Fluticasone furoate, a novel inhaled corticosteroid, demonstrates prolonged lung absorption kinetics in man compared with inhaled fluticasone propionate","volume":"52","author":"Allen","year":"2013","journal-title":"Cli. Pharmacokinet."},{"key":"B2","doi-asserted-by":"crossref","DOI":"10.1002\/9780470773666","volume-title":"Statistical methods in medical Research","author":"Armitage","year":"2002"},{"key":"B3","first-page":"55","article-title":"Estimating sample size and power: Applications and examples","volume-title":"Designing clinical Research","author":"Browner","year":"2013"},{"key":"B4","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1016\/j.ejphar.2015.05.020","article-title":"Pharmacological interaction between LABAs and LAMAs in the airways: Optimizing synergy","volume":"761","author":"Calzetta","year":"2015","journal-title":"Eur. J. Pharmacol."},{"key":"B5","doi-asserted-by":"publisher","first-page":"450","DOI":"10.1124\/pr.111.004580","article-title":"Pharmacology and therapeutics of bronchodilators","volume":"64","author":"Cazzola","year":"2012","journal-title":"Pharmacol. Rev."},{"key":"B6","volume-title":"Basic & clinical biostatistics","author":"Dawson","year":"2004"},{"key":"B7","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1016\/j.resp.2012.08.022","article-title":"Bronchodilation of umeclidinium, a new long-acting muscarinic antagonist, in COPD patients","volume":"185","author":"Decramer","year":"2013","journal-title":"Respir. Physiol. Neurobiol."},{"key":"B8","doi-asserted-by":"publisher","first-page":"970","DOI":"10.1016\/j.rmed.2012.03.012","article-title":"A randomized, double-blind dose-ranging study of the novel LAMA GSK573719 in patients with COPD","volume":"106","author":"Donohue","year":"2012","journal-title":"Respir. Med."},{"key":"B9","doi-asserted-by":"publisher","first-page":"1538","DOI":"10.1016\/j.rmed.2013.06.001","article-title":"Efficacy and safety of once-daily umeclidinium\/vilanterol 62.5\/25 mcg in COPD","volume":"107","author":"Donohue","year":"2013","journal-title":"Respir. Med."},{"key":"B10","doi-asserted-by":"publisher","first-page":"719","DOI":"10.2147\/COPD.S102494","article-title":"A randomized, blinded study to evaluate the efficacy and safety of umeclidinium 62.5 \u03bcg compared with tiotropium 18 \u03bcg in patients with COPD","volume":"11","author":"Feldman","year":"2016","journal-title":"Int. J. Chron. Obstruct. Pulmon. Dis."},{"key":"B11","doi-asserted-by":"publisher","first-page":"761","DOI":"10.1080\/13543784.2017.1319472","article-title":"Umeclidinium for the treatment of uncontrolled asthma","volume":"26","author":"Ferrando","year":"2017","journal-title":"Expert opi. Investig. Drugs"},{"key":"B12","doi-asserted-by":"publisher","first-page":"1590","DOI":"10.3390\/ijms17091590","article-title":"Involvement of Ca2+ signaling in the synergistic effects between muscarinic receptor antagonists and \u03b22-adrenoceptor agonists in airway smooth muscle","volume":"17","author":"Fukunaga","year":"2016","journal-title":"Int. J. Mol. Sci."},{"key":"B13","volume-title":"Global strategy for asthma management and prevention","author":"Global Initiative for Asthma","year":"2018"},{"key":"B14","unstructured":"Global strategy for asthma management and prevention\n            Global Initiative for Asthma\n          2022"},{"key":"B15","doi-asserted-by":"publisher","first-page":"1804","DOI":"10.1111\/j.1476-5381.2012.01881.x","article-title":"Regional quantification of muscarinic acetylcholine receptors and \u03b2-adrenoceptors in human airways","volume":"166","author":"Ikeda","year":"2012","journal-title":"Br. J. Pharmacol."},{"key":"B16","doi-asserted-by":"crossref","DOI":"10.1017\/CBO9780511974175","volume-title":"Multivariable analysis: A practical guide for clinicians and public Health researchers","author":"Katz","year":"2011"},{"key":"B17","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1016\/S2213-2600(20)30389-1","article-title":"Efficacy and safety of once-daily single-inhaler triple therapy (FF\/UMEC\/VI) versus FF\/VI in patients with inadequately controlled asthma (CAPTAIN): A double-blind, randomised, phase 3A trial","volume":"9","author":"Lee","year":"2021","journal-title":"Lancet Respir. Med."},{"key":"B18","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1016\/j.rmed.2014.10.009","article-title":"A randomized, three-period crossover study of umeclidinium as monotherapy in adult patients with asthma","volume":"109","author":"Lee","year":"2015","journal-title":"Respir. Med."},{"key":"B19","doi-asserted-by":"publisher","first-page":"4121","DOI":"10.3892\/mmr.2015.3307","article-title":"A long-acting \u03b22-adrenergic agonist increases the expression of muscarine cholinergic subtype-3 receptors by activating the \u03b22-adrenoceptor cyclic adenosine monophosphate signaling pathway in airway smooth muscle cells","volume":"11","author":"Liu","year":"2015","journal-title":"Mol. Med. Rep."},{"key":"B20","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1177\/1753465814559209","article-title":"Effects of a combination of umeclidinium\/vilanterol on exercise endurance in patients with chronic obstructive pulmonary disease: Two randomized, double-blind clinical trials","volume":"8","author":"Maltais","year":"2014","journal-title":"Ther. Adv. Respir. Dis."},{"key":"B21","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1016\/j.pupt.2018.01.003","article-title":"Comparison of the in vitro pharmacological profiles of long-acting muscarinic antagonists in human bronchus","volume":"49","author":"Naline","year":"2018","journal-title":"Pulm. Pharmacol. Ther."},{"key":"B22","first-page":"171","article-title":"Designing studies of medical tests","volume-title":"Designing clinical Research","author":"Newman","year":"2013"},{"key":"B23","doi-asserted-by":"publisher","first-page":"542769","DOI":"10.1155\/2012\/542769","article-title":"Lung compliance and chronic obstructive pulmonary disease","volume":"2012","author":"Papandrinopoulou","year":"2012","journal-title":"Pulm. Med."},{"key":"B24","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1016\/j.coph.2014.03.005","article-title":"Crosstalk between beta-2-adrenoceptor and muscarinic acetylcholine receptors in the airway","volume":"16","author":"Pera","year":"2014","journal-title":"Curr. Opin. Pharmacol."},{"key":"B25","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1007\/s40265-015-0532-5","article-title":"Inhaled umeclidinium in COPD patients: A review and meta-analysis","volume":"76","author":"Pleasants","year":"2016","journal-title":"Drugs"},{"key":"B26","first-page":"833","article-title":"Use of inhaled anticholinergic agents in obstructive airway disease","volume":"52","author":"Restrepo","year":"2007","journal-title":"Respir. Care"},{"key":"B27","doi-asserted-by":"publisher","first-page":"260","DOI":"10.1124\/jpet.112.202051","article-title":"Pharmacological characterization of GSK573719 (umeclidinium): A novel, long-acting, inhaled antagonist of the muscarinic cholinergic receptors for treatment of pulmonary diseases","volume":"345","author":"Salmon","year":"2013","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"B28","doi-asserted-by":"publisher","first-page":"203","DOI":"10.2147\/COPD.S145285","article-title":"Relationship between exercise endurance and static hyperinflation in a post hoc analysis of two clinical trials in patients with COPD","volume":"13","author":"Singh","year":"2018","journal-title":"Int. J. Chron. Obstruct. Pulmon. Dis."},{"key":"B29","doi-asserted-by":"publisher","first-page":"218","DOI":"10.1124\/jpet.112.198481","article-title":"In vitro pharmacological characterization of vilanterol, a novel long-acting \u03b22-adrenoceptor agonist with 24-hour duration of action","volume":"344","author":"Slack","year":"2013","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"B30","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1016\/j.ejphar.2012.12.019","article-title":"Initial assessment of single and repeat doses of inhaled umeclidinium in patients with chronic obstructive pulmonary disease: Two randomised studies","volume":"701","author":"Tal-Singer","year":"2013","journal-title":"Eur. J. Pharmacol."},{"key":"B31","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1183\/09031936.00033213","article-title":"Umeclidinium in patients with COPD: A randomised, placebo-controlled study","volume":"43","author":"Trivedi","year":"2014","journal-title":"Eur. Respir. J."},{"key":"B32","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1080\/2331205X.2019.1600632","article-title":"Real-world efficacy and problems of once-daily use of inhaled steroid (fluticasone furoate) combined with long-acting beta-2 agonist (vilanterol) in Japanese patients with asthma","volume":"6","author":"Umeda","year":"2019","journal-title":"Cogent Med."},{"key":"B33","first-page":"70","volume-title":"Airway obstruction\u201d in west\u2019s pulmonary pathophysiology, the essentials","author":"West","year":""},{"key":"B34","first-page":"11","article-title":"Maximum flows from the flow-volume curve","volume-title":"West\u2019s pulmonary pathophysiology, the essentials","author":"West","year":""},{"key":"B35","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1016\/j.pupt.2016.11.004","article-title":"Effects of tiotropium on lung function in current smokers and never smokers with bronchial asthma","volume":"42","author":"Yoshida","year":"2017","journal-title":"Pulm. Pharmacol. Ther."},{"key":"B36","doi-asserted-by":"publisher","first-page":"809","DOI":"10.2147\/COPD.S215011","article-title":"Efficacy and safety of once-daily inhaled umeclidinium in asian patients with COPD: Results from a randomized, placebo-controlled study","volume":"15","author":"Zhong","year":"2020","journal-title":"Int. J. Chron. Obstruct. Pulmon. Dis."}],"container-title":["Frontiers in Physiology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphys.2023.1131949\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,11]],"date-time":"2023-05-11T11:29:01Z","timestamp":1683804541000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphys.2023.1131949\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,4,21]]},"references-count":36,"alternative-id":["10.3389\/fphys.2023.1131949"],"URL":"https:\/\/doi.org\/10.3389\/fphys.2023.1131949","relation":{},"ISSN":["1664-042X"],"issn-type":[{"value":"1664-042X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,4,21]]},"article-number":"1131949"}}